Modern clinical research into immunotherapy and alternative treatments for lymphomas
Creators: name: Lambert, Danielle
name: Repass, Kaitlin
name: Testo, George
Publisher: name: Zenodo
Year: 2021
Subjects: Hodgkin's lymphoma
Non-Hodgkin's lymphoma
Immune therapies
CAR-T Cell

description: Hodgkin’s lymphoma (HL) and Non-Hodgkin’s lymphoma (NHL) are clinically recognized as cancers of the lymphatic system affecting approximately 10% of cancer patients. HL and NHL are characterized by the presence of malignant cells and immune effector cells. After second-line immunotherapy, most patients tend to have a higher probability of relapse due to the resilience of their illnesses. When evaluating survivability and the effectiveness of medications for patients with lymphomas, it is important to consider the use of prognostic biomarkers for those who may have an increased risk of pathogenesis. Most lymphomas arise from clonal expansion of B, T, or natural killer cells at stages of differentiation. Since these types of cells occur in immunocyte-rich lymphoid tissues, they are easily accessible via cell-based immunochemotherapy. Expression of chimeric antigen receptors (CAR) in T-cells combines antigen-binding sites of monoclonal antibodies with the activating machinery of T- cells. This specific antibody response supports antigen recognition and other antitumor properties of T-cells. Chimeric antigen receptors are specifically useful for allowing T-cells to target a range of cancer related proteins. Modern methods and strategies for the treatment of HL and NHL can provide patients relief from symptoms associated with lymphatic inflammation. Based on previous studies, more funding and support for research studies on the dynamics of lymphomas will be necessary. In this literature-based review, we provide an overview of modern research on immunotherapies.
description: {"references": ["Ansell, S. M. Hodgkin lymphoma: A 2020 update on diagnosis, risk-stratification, and management. Am. J. Hematol. 95, 978\u2013989 (2020).", "Shanbhag, S. &amp; Ambinder, R. F. Hodgkin lymphoma: A review and update on recent progress. CA Cancer J. Clin. 68, 116\u2013132 (2018).", "Kim, Y. R. et al. Different roles of surveillance positron emission tomography according to the histologic subtype of non-Hodgkin's lymphoma. Korean J. Intern. Med. (2020) doi:10.3904/kjim.2019.376.", "Khare, D. et al. Plasma microRNA profiling: Exploring better biomarkers for lymphoma surveillance. PLoS One 12, e0187722 (2017).", "Ayers, E. C. et al. Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure. Cancer 126, 293\u2013303 (2020).", "Farkona, S., Diamandis, E. P. &amp; Blasutig, I. M. Cancer immunotherapy: the beginning of the end of cancer? BMC Med. 14, 73 (2016).", "Fuertes, T., Ramiro, A. R. &amp; de Yebenes, V. G. miRNA-Based Therapies in B Cell Non-Hodgkin Lymphoma. Trends Immunol. 41, 932\u2013947 (2020).", "Younes, A. et al. The landscape of new drugs in lymphoma. Nat. Rev. Clin. Oncol. 14, 335\u2013346 (2017).", "O'Connor, O. A. Developing new drugs for the treatment of lymphoma: New drugs in lymphoma. Eur. J. Haematol. 75, 150\u2013158 (2005)."]}